As leader of Novo Nordisk’s medical device research unit in Seattle, Thomas Dedenroth Miller champions the use of digital health solutions and novel drug/device combinations to improve disease management. Since joining the company in 2000, Miller has served as a key member of the teams that developed renowned diabetes devices such as the FlexTouch and FlexPro pens.
Most recently, Miller has turned his attention to the company’s work with external technology partners on connectivity and mobile medication decision systems. He has done so through programs such as the Novo Nordisk Innovation Challenge, which enlists digital innovators to develop new ways to use data generated by Novo Nordisk’s pen injectors.
Miller also plays an integral role in soliciting input from patients and healthcare providers to further Novo Nordisk’s device innovation. As part of this effort, he leverages insights from a multidisciplinary team consisting of engineers, designers, data scientists, healthcare professionals and anthropologists.
From the May 01, 2019 Issue of MM+M - Medical Marketing and Media
